跳至主要内容
临床试验/NCT04035525
NCT04035525Unknown不适用

Pharmacokinetic Study on Three Formulations of Coenzyme Q10 With Different Carriers

Mélanie Plourde2 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2020年3月4日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
30
试验地点
2
主要终点
Determine the bioavailability of CoQ10 in combination with fish oil, rice oil or alone: Calculating the time when the maximum concentration is reached, as the fourth parameter of the PK

研究概览

简要总结

Coenzyme Q10 (CoQ10) is a vitamin-like substance produced in all living human cells and naturally occurring in dietary sources. In addition to being responsible for the synthesis of adenosine triphosphate (ATP), a major source of energy, CoQ10 plays an essential role in maintaining several biochemical pathways of the human body: i) it acts as a primary scavenger of free radicals, and ii) it protects membranes phospholipids from peroxidation and membranes proteins and mitochondrial DNA from oxidative damage. Despite the potential impact that it has shown in a wide array of health conditions, CoQ10 has been reported to have a poor bioavailability in humans with a slow and incomplete absorption from the small intestine. This has been attributed to its high molecular weight, strongly lipophilic nature and low aqueous solubility. To overcome the above limitations, various drug delivery systems such as liposomes, polymeric nanoparticles, polymeric micelles, solid lipid nanoparticles, nanostructured lipid carriers, self-emulsifying systems, nanoemulsions and solid and aqueous dispersions have been explored and developed to improve the solubility, the absorption and the bioavailability of CoQ10. Even though these different technologies and delivery systems were able to improve the absorption of CoQ10 and increase its bioavailability, the carriers used to deliver CoQ10 are based on synthetic products with no health benefits attributed to them. Aligned with its mission and vision to provide its clients with wellness products, Biodroga Neutraceuticals Inc developped a CoQ10 product using its patented MaxSimil technology that is based on omega-3 fatty acids (EPA and DHA) and this health product will be serving as the carrier for CoQ10. Therefore, the aim of this study is to perform a PK study using a powder product of CoQ10 and a rice bran oil + CoQ10 forms as comparators to the MaxSimil® + CoQ10 omega-3 supplement and compare their bioavailability and side effects. In this context, a randomized crossover design with a minimum of 7 days of washout between treatments will be used. The MaxSimil® + CoQ10 formulation is anticipated to provide the best vehicle to increase the bioavailability of CoQ10 with the lowest side effects for the participants.

详细描述

Benefits and importance of CoQ10 for the human health:

Coenzyme Q10 (CoQ10) is an endogenously produced lipid-soluble molecule of the human organism that is considered an essential component of the mitochondrial electron transport chain where it is the electron acceptor for complexes I and II. In this context, CoQ10 plays a key role in mitochondrial oxidative phosphorylation and ATP production and therefore it is essential for all energy-dependent processes in the body, enhancing the immune-system and acting as a free radical scavenger. In addition to its abundant presence in the mitochondrion, CoQ10 is found in other organelles such as endoplasmic reticulum, peroxisomes, lysosomes and vesicles. It is a membrane stabilizer, preserves myocardial sodium-potassium ATPase activity, and stabilizes myocardial calcium-dependent ion channels. Several factors such as ageing, poor eating habits, stress and infection, are known to affect the organism's ability to continue synthesizing and providing the adequate amounts of CoQ10. With age, the human organism begins to develop a CoQ10 deficiency due to its inability to synthesize it from food where it is present in beef, poultry, broccoli, soya oil and peanuts. In this context, several researchers have advised using CoQ10 supplements alone or in combination with other nutritional supplements to alleviate this deficiency and help maintain health of elderly people or treat some of the health problems or diseases. Due to these functions, CoQ10 finds its application in different commercial branches such as food, cosmetic, or pharmaceutical industries. The antioxidant activity of CoQ10 surpasses both in the amount and in efficiency other antioxidants. The protective effect is extended to lipids proteins and DNA mainly because of its close localization to the oxidative events and the effective regeneration by continuous reduction at all locations. CoQ10 in its reduced form as a hydroquinone (ubiquinol) is a potent lipophilic antioxidant that has a great importance as a free radical scavenger. CoQ10 protects the stability of the cell membranes, protects DNA from free radical induced oxidative damage, and is capable of recycling and regenerating other antioxidants, such as tocopherol and ascorbate. Other important functions of CoQ10 as e.g. cell signaling and gene expression have also been described.

Absorption and Transport of CoQ10:

Taking its lipophilic nature, the absorption of CoQ10 is enhanced in the presence of lipids with the main role attributed to the intestinal secretions from the pancreas and bile that are known to facilitate emulsification and micelle formation required for the fats absorption. Either during or following its absorption in the intestine, CoQ10 is reduced to ubiquinol, incorporated into chylomicrons and then transported via the lymphatics to the circulation where about 95% of CoQ10 in circulation exists in its reduced form as ubiquinol in human subjects. Plasma CoQ10 concentrations are highly dependent on plasma lipoproteins where CoQ10 redistributes possibly to protect lipoproteins from oxidation. Several factors have highlighted the poor absorption of orally administered CoQ10 such as its insolubility in water, limited solubility in lipids, and relatively large molecular weight. A preclinical study has reported that only about 2-3% of orally-administered CoQ10 was absorbed. Additionally, the absorption of CoQ10 and its bioavailability have been shown to be dependent on other factors such as the nature of the formulation of CoQ10 with solubilized formulations been reported to have an advanced effect on the bioavailability.

Tissue distribution of CoQ10 in humans and animals:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Neither the participant nor the research nurse will know the administration order of the different treatments administered. All plasma samples collected during the research project will be anonymized i.e. it will not be possible to identify the participant by his name since a number will be assigned to him. The code key linking the participant's name to his number will be stored, with access restricted to those designated by the principal investigator. The data file is also protected by a password.

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Man or woman between 18 and 50 years old (inclusive).
  • Body mass index between 18,5 and 34,9 at the selection visit (inclusive).
  • Normal to moderately elevated lipidemia (total cholesterol ≤ 240 mg / dl, LDL ≤ 160 mg / dl, TG ≤ 199 mg / dl).
  • Woman of child bearing potential must accept to use an effective contraceptive method for the duration of the study.

排除标准

  • Current or past performance athlete.
  • Allergy to fish or seafood.
  • Special diet like a fat-free, vegetarian or vegan diet.
  • Menopause or pre-menopause with amenorrhea > 6 months.
  • History of current or past alcohol and / or drug abuse.
  • Pregnant women or nursing women.
  • Malnutrition (assessed by albumin, hemoglobin and blood lipid levels).
  • Systemic disease: vasculitis, Lupus Erythrocyte Disseminated (SLE), sarcoidosis, cancer (except if in remission for more than 10 years and without cerebral involvement), uncompensated hypothyroidism, vitamin B12 deficiency not supplemented and / or complicated, diabetes, insufficiency severe renal.
  • Abnormal liver, kidney or thyroid function; these conditions will not exclude a patient if he / she has been stabilized on treatment for at least 3 months and there has been no recent change in his / her medication.
  • Cardiac event or recent major surgery (<6 months).
  • Person with a history of thrombosis or haemorrhagic diathesis.
  • People who have a malabsorption disease such as pancreatitis, Crohn's disease or who have had bariatric surgery.
  • Hypo or hypertension.
  • People consuming omega 3 fatty acid supplements for more than 6 months.
  • Parkinson disease.
  • Down syndrome.
  • Known psychiatric history: schizophrenia, psychotic disorders, major affective disorder (bipolar disorder and major depression <5 years), panic disorder, Compulsive Obsessive Compulsive Disorder (OCD).
  • Epilepsy, cerebral trauma with loss of consciousness, subarachnoid hemorrhage.
  • Medication affecting fat absorption (ie, Orlistat, Alli, etc.), which interferes with the uptake of omega-3 fatty acids (ie, anticoagulants like coumadin, aspirin is not an exclusion criterion (Watson et al, 2009)), which affects lipid metabolism (ie, all types of drugs to lower cholesterol or triglycerides) or which affect CoQ10 blood levels (b-blockers and hypoglycemic agents).
  • Person who has donated blood or had significant blood loss in the 30 days prior to the start of the study.
  • Not available to perform the 3 different treatments.

结局指标

主要结局

Determine the bioavailability of CoQ10 in combination with fish oil, rice oil or alone: Calculating the time when the maximum concentration is reached, as the fourth parameter of the PK

时间窗: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. HPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours post-treatment.

Plasma CoQ10 levels will be measured by high-performance liquid chromatography (HPLC), each sample being performed randomly blindly. After HPLC analyzes, time when the maximum concentration is reached will be calculated, as the fourth parameter of the PK. Statistical analyzes will then be performed on this PK parameter.

Determine the bioavailability of CoQ10 in combination with fish oil, rice oil or alone: Calculating the AUC 0-6h (absorption study) as the second parameter of the PK

时间窗: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. HPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours post-treatment.

Plasma CoQ10 levels will be measured by high-performance liquid chromatography (HPLC), each sample being performed randomly blindly. After HPLC analyzes, AUC 0-6 hours (absorption study) will be calculated, as the second parameter of the PK. Statistical analyzes will then be performed on this PK parameter.

Determine the bioavailability of CoQ10 in combination with fish oil, rice oil or alone: Calculating the maximum concentration as the third parameter of the PK.

时间窗: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. HPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours post-treatment.

Plasma CoQ10 levels will be measured by high-performance liquid chromatography (HPLC), each sample being performed randomly blindly. After HPLC analyzes, maximum concentration will be calculated, as the third parameter of the PK. Statistical analyzes will then be performed on this PK parameter.

Determine the bioavailability of CoQ10 in combination with fish oil, rice oil or alone: Calculating the area under the curve (AUC) 0-48h as the first parameter of the PK

时间窗: Treatments are randomly assigned on days 1, 8 and 15 of the clinical study. HPLC analyzes will be measured on plasma from blood samples collected at time 0, 1, 2, 4, 5, 6, 8, 10, 12, 24 and 48 hours post-treatment.

Plasma CoQ10 levels will be measured by high-performance liquid chromatography (HPLC), each sample being performed randomly blindly. After HPLC analyzes, area under the curve (AUC) 0-48 hours will be calculated, as the first parameter of the PK. Statistical analyzes will then be performed on this PK parameter.

次要结局

未报告次要终点

研究者

发起方
Mélanie Plourde
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Mélanie Plourde

Principal investigator

Université de Sherbrooke

研究点 (2)

Loading locations...

相似试验